Carboxy-PTIO

Cat. No.: HY-18734 CAS No.: 145757-47-7 Molecular Formula: $C_{14}H_{17}N_2O_4$

Molecular Weight: 277.3

Target: NO Synthase

Pathway: Immunology/Inflammation

Please store the product under the recommended conditions in the Certificate of Storage:

Analysis.

Product Data Sheet

BIOLOGICAL ACTIVITY

Description

Carboxy-PTIO is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharidestimulated rat model^{[1][2][3]}.

In Vitro

Carboxy-PTIO (200 µM; 1 h prior to physalin A; 24 hours) significantly suppresses the stimulation of NO expression induced by physalin A treatment, but no change is observed in Carboxy-PTIO treatment alone [1].

Carboxy-PTIO (200 µM; 1 h prior to physalin A; 24 hours) reduces physalin A-induced cleavage of procaspase-3 and PARP, down-regulated ICAD expression, diminishing DNA fragmentation in nuclei^[1].

Carboxy-PTIO (200 µM; 1 h prior to physalin A; 24 hours) shows no effect on iNOS expression. However, decreased-mTOR and p-mTOR levels induced by physalin A is reversed by Carboxy-PTIO with concomitant suppression of LC3 I to LC3 II conversions in A375-S2 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	A375-S2 cells
Concentration:	200 μΜ
Incubation Time:	1 h prior to physalin A; 24 hours
Result:	Diminished physalin A-induced procaspase-3 and PARP cleavage.

In Vivo

Carboxy-PTIO (intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min) treatment improves the hypotension, renal dysfunction and survival rate in Lps-treated rats. But it does not affect each parameter in naomal rats^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SD rats ^[3]
Dosage:	0.056-1.70 mg/kg/min
Administration:	Intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min

Result:	Exhibited a potent therapeutic value in endotoxin shock through the direct scavengin
	action against NO.

REFERENCES

- [1]. Hao He, et al.Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells. Food Chem Toxicol. 2014 Sep;71:128-35.
- [2]. T Akaike, et al. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry. 1993 Jan 26;32(3):827-32.
- [3]. M Yoshid, et al. Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity. Biochem Biophys Res Commun. 1994 Jul 29;202(2):923-30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA